专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1991006674A1 METHOD AND DEVICE FOR THE DETECTION OF ANTIBIOTIC RESISTANCE 审中-公开
标题翻译：用于检测抗生素耐药性的方法和装置
公开(公告)号：WO1991006674A1
公开(公告)日：1991-05-16
申请号：PCT/GB1990001697
申请日：1990-11-06
申请人： SCOTGEN LTD. , HARRIS, William, Joseph , CARR, Francis, Joseph
发明人： SCOTGEN LTD.
IPC分类号： C12Q01/68
CPC分类号： C12Q1/6834 , C12Q1/18 , C12Q1/6876 , C12Q1/689
摘要： A method for the quick and easy detection of antibiotic resistance in a sample and a kit that incorporates this method. The method involves providing a support; a first probe capable of specifically binding to part of the nucleic acid encoding the antibiotic resistance, and which is immobilisable on the support before and during the test procedure; a second probe capable of specifically binding another part of the nucleic acid encoding the antibiotic resistance, this second probe being labelled so as to be capable of producing a signal; allowing nucleic acid from the sample to come into contact with the first probe and the labelled second probe; detecting any signal from the labelled second probe bound to the support by cohybridisation of the immobilised first probe and the labelled probe to antibiotic resistance nucleic acid.
摘要翻译：用于快速和容易地检测样品中的抗生素抗性的方法和包含该方法的试剂盒。该方法涉及提供支持; 能够特异性结合编码抗生素抗性的核酸的一部分的第一探针，并且其可在测试过程之前和期间固定在载体上; 能够特异性结合编码抗生素抗性的核酸的另一部分的第二探针，该第二探针被标记以能够产生信号; 允许来自样品的核酸与第一探针和标记的第二探针接触; 通过将固定化的第一探针和标记的探针共同杂交到抗生素抗性核酸上，检测与标记的第二探针结合的载体的任何信号。

2. 发明申请

WO2009023185A1 CANCER TREATMENT USING HUMANIZED ANTIBODIES THAT BIND TO EPHB4 审中-公开
标题翻译：使用与EPHB4结合的人类抗体的癌症治疗
公开(公告)号：WO2009023185A1
公开(公告)日：2009-02-19
申请号：PCT/US2008/009619
申请日：2008-08-11
申请人： VASGENE THERAPEUTICS, INC. , CARR, Francis, Joseph , GILL, Parkash , JONES, Timothy, David , KEEN, Simon, William , KRASNOPEROV, Valery
发明人： CARR, Francis, Joseph , GILL, Parkash , JONES, Timothy, David , KEEN, Simon, William , KRASNOPEROV, Valery
IPC分类号： C07K16/28 , C07K16/30
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567
摘要： In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes.
摘要翻译：在某些实施方案中，本申请提供结合EphB4蛋白的人源化抗体以及抗体用于治疗目的的用途。

3. 发明申请

WO2013036574A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A 审中-公开
标题翻译：假单胞菌外毒素A的修饰形式
公开(公告)号：WO2013036574A1
公开(公告)日：2013-03-14
申请号：PCT/US2012/053868
申请日：2012-09-06
申请人： INTREXON CORPORATION , JONES, Timothy, David , CARR, Francis, Joseph
发明人： JONES, Timothy, David , CARR, Francis, Joseph
IPC分类号： A61K39/02 , A61K39/108 , A61K39/00
CPC分类号： C12N9/1077 , A61K38/00 , A61K39/00 , A61K39/02 , C07K14/21 , C07K16/2803 , C07K2317/622 , C12Y204/02036
摘要： Pseudomonas exotoxin A or "PE" is a 66kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
摘要翻译：假单胞菌外毒素A或“PE” 是由细菌铜绿假单胞菌分泌的66kD，高效的细胞毒性蛋白质。已经将多种形式的PE与其他蛋白质（例如抗体）偶联以产生治疗上有用的细胞毒素缀合物，其选择性靶向所需的表型（如肿瘤细胞）。在本发明中，分析跨越假单胞菌外毒素A蛋白的约38kD形式的序列的肽的免疫原性CD4 + T细胞表位的存在。鉴定了六种免疫原性T细胞表位。在每个表位内鉴定残基以引入靶向氨基酸取代以减少或阻止PE分子中可以施用于异源宿主的免疫原性T细胞应答。

4. 发明申请

WO1994009136A1 RECOMBINANT HUMANIZED ANTI-CYTOMEGALOVIRUS ANTIBODIES 审中-公开
标题翻译：重组人类抗细胞免疫球蛋白抗体
公开(公告)号：WO1994009136A1
公开(公告)日：1994-04-28
申请号：PCT/GB1993002134
申请日：1993-10-15
申请人： KETTOCK LODGE, CAMPUS 2 , HARRIS, William, Joseph , CARR, Francis, Joseph , HAMILTON, Anita, Anne
发明人： KETTOCK LODGE, CAMPUS 2
IPC分类号： C12N15/13
CPC分类号： C07K16/088 , A61K38/00 , C07K16/461 , C07K2317/24
摘要： A humanised monoclonal antibody, or antigen-binding fragment thereof, which binds to the gH glycoprotein of HCMV, and has HCMV-neutralising activity. Its CDRs are derived from a non-human antibody and its FRs are derived from a human antibody. Certain amino acids of the human FRs have been altered to improve the HCMV-specificity and/or affinity of the antibody.
摘要翻译：与HCMV的gH糖蛋白结合并具有HCMV中和活性的人源化单克隆抗体或其抗原结合片段。其CDRs来自非人抗体，其FR来自人抗体。已经改变人FR的某些氨基酸以改善抗体的HCMV特异性和/或亲和力。

5. 发明申请

WO2004074486A3 FUSION PROTEINS OF INTERFERON ALPHA MUTEINS WITH IMPROVED PROPERTIES 审中-公开
公开(公告)号：WO2004074486A3
公开(公告)日：2004-09-02
申请号：PCT/EP2004/001524
申请日：2004-02-18
申请人： MERCK PATENT GMBH , JONES, Tim , BAKER, Matthew , HANLON, Marian , CARR, Francis, Joseph
发明人： JONES, Tim , BAKER, Matthew , HANLON, Marian , CARR, Francis, Joseph
IPC分类号： C12N15/21
摘要： The invention concerns human interferon alpha and in particular modified forms of interferon alpha 2 with improved properties. The improved proteins contain amino acid substitutions at specific positions that confer increased relative activity in biological assays. The invention provides also modified interferon alpha with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.

6. 发明申请

WO2004074486A2 FUSION PROTEINS OF INTERFERON ALPHA MUTEINS WITH IMPROVED PROPERTIES 审中-公开
标题翻译：具有改善性质的干扰素ALPHA MUTEIN的融合蛋白
公开(公告)号：WO2004074486A2
公开(公告)日：2004-09-02
申请号：PCT/EP2004001524
申请日：2004-02-18
申请人： MERCK PATENT GMBH , JONES TIM , BAKER MATTHEW , HANLON MARIAN , CARR FRANCIS JOSEPH
发明人： JONES TIM , BAKER MATTHEW , HANLON MARIAN , CARR FRANCIS JOSEPH
IPC分类号： A61K38/21 , C07K14/56 , C12N15/21
CPC分类号： A61K38/212 , C07K14/56 , C07K2319/30
摘要： The invention concerns human interferon alpha and in particular modified forms of interferon alpha 2 with improved properties. The improved proteins contain amino acid substitutions at specific positions that confer increased relative activity in biological assays. The invention provides also modified interferon alpha with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.
摘要翻译：本发明涉及人类干扰素α，特别涉及具有改进性质的干扰素α2的修饰形式。改进的蛋白质在特定位置含有氨基酸取代，其在生物测定中赋予增加的相对活性。本发明还提供修饰的干扰素α，其具有改善的生物活性，伴随蛋白质中的免疫原性潜力降低。改进的蛋白质用于治疗人类疾病的治疗用途。

7. 发明申请

WO0034317A3 METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS 审中-公开
标题翻译：降低蛋白质免疫原性的方法
公开(公告)号：WO0034317A3
公开(公告)日：2000-08-17
申请号：PCT/GB9904119
申请日：1999-12-08
申请人： BIOVATION LTD , CARR FRANCIS JOSEPH , ADAIR FIONA SUZANNE , HAMILTON ANITA ANNE , CARTER GRAHAM
发明人： CARR FRANCIS JOSEPH , ADAIR FIONA SUZANNE , HAMILTON ANITA ANNE , CARTER GRAHAM
IPC分类号： G01N33/50 , A61K38/00 , C07K1/00 , C07K14/315 , C07K14/435 , C07K14/47 , C07K16/46 , C12N9/48 , C12N9/70 , C12N15/09 , C12P21/02 , G01N33/15 , G01N33/563
CPC分类号： G01N33/6878 , C07K14/31 , C07K14/56 , C12N9/6418 , G01N2333/70503 , Y02A90/26
摘要： It is known that proteins, or parts of them, may be rendered non- or less immunogenic to humans or other species by identifying one or more potential T cell epitopes and eliminating them by amino acid modification. Conventionally, certain epitopes may be retained in a protein sequence if the peptides constituting such epitopes are present in endogenous human protein, since they would be recognised as "self". However, it has now been found that even self epitopes may give rise to immune reactions. The invention provides for their elimination, for example by recombinant DNA technology, to render them more useful for administration to humans, for example for therapeutic or diagnostic purposes.
摘要翻译：已知通过鉴定一个或多个潜在的T细胞表位并通过氨基酸修饰来消除它们，蛋白质或其部分可能对人或其它物种具有或不低的免疫原性。通常，如果构成这种表位的肽存在于内源性人蛋白质中，则某些表位可以保留在蛋白质序列中，因为它们将被认为是“自身”。然而，现在已经发现即使自身表位也可能引起免疫反应。本发明例如通过重组DNA技术提供它们的消除，使其更适用于给予人类，例如用于治疗或诊断目的。

8. 发明申请

WO1996025952A1 PHARMACEUTICALS AND ASSAYS USING ENZYME SUBUNITS 审中-公开
标题翻译：使用酶亚基的药物和测定
公开(公告)号：WO1996025952A1
公开(公告)日：1996-08-29
申请号：PCT/GB1996000380
申请日：1996-02-21
申请人： THE SECRETARY OF STATE FOR DEFENCE , TITBALL, Richard, William , CARR, Francis, Joseph
发明人： THE SECRETARY OF STATE FOR DEFENCE
IPC分类号： A61K47/48
CPC分类号： G01N33/581 , A61K9/127 , A61K47/6851 , A61K47/6899 , B82Y5/00 , Y02A50/411 , Y10S435/81 , Y10S977/907
摘要： A method of releasing an agent (e.g. a chemotherapeutic) under predetermined conditions comprising the steps of protecting the agent within a lipid structure (e.g. a liposome), causing lipase activity to be constituted by combining two or more components (e.g. recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments), one of these components being conjugated to a targeting molecule (e.g. an antibody) which binds to a target (e.g. a tumour antigen) under the predetermined conditions. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclosed are materials and kits for use in the method.
摘要翻译：一种在预定条件下释放试剂（例如化学治疗剂）的方法，包括以下步骤：在脂质结构（例如脂质体）内保护试剂，引起脂肪酶活性通过组合两种或多种组分（例如重组N-或C - 产气荚膜梭菌α-毒素片段），这些成分之一与预定条件下与靶标（例如肿瘤抗原）结合的靶向分子（例如抗体）缀合。然后将脂质结构暴露于构成的脂肪酶活性，以释放该药剂。还公开了用于该方法的材料和试剂盒。

9. 发明申请

WO1994009131A1 RECOMBINANT SPECIFIC BINDING PROTEIN 审中-公开
标题翻译：重组特异性结合蛋白
公开(公告)号：WO1994009131A1
公开(公告)日：1994-04-28
申请号：PCT/GB1993002133
申请日：1993-10-15
申请人： SCOTGEN LIMITED , HARRIS, William, Joseph , EMERY, Stephen, Charles , WINTER, Gregory, Paul , CARR, Francis, Joseph , MCGREGOR, Duncan, Patrick
发明人： SCOTGEN LIMITED
IPC分类号： C12N15/12
CPC分类号： C07K16/468 , A61K38/00
摘要： A specific binding protein having first and second binding regions, e.g. antibody Fv fragments, which specifically recognise and bind to target entities, said binding regions being contained at least in part on respectively first and second polypeptide chains, said chains additionally incorporating respectively first and second associating domains, e.g. antibody VH and VL domains, which are capable of binding to each other, causing the first and second polypeptide chains to combine, thereby providing a single protein incorporating the binding specificities of said first and second binding regions. The first and second binding regions may recognise different target entities, giving a bispecific binding protein. Preferably the associating domains are derived from a human protein (i.e. one which has been exposed to the human immune system), so that the protein is less likely to provoke the human immune system when administered therapeutically. The binding protein is suitably produced by recombinant DNA expression.
摘要翻译：具有第一和第二结合区的特异性结合蛋白，例如抗体Fv片段，其特异性识别并结合靶物质，所述结合区至少部分地分别包含第一和第二多肽链，所述链另外包含第一和第二缔合结构域，例如，抗体VH和VL结构域，其能够彼此结合，导致第一和第二多肽链结合，从而提供掺入所述第一和第二结合区的结合特异性的单一蛋白质。第一和第二结合区可以识别不同的靶实体，得到双特异性结合蛋白。优选地，缔合结构域衍生自人蛋白质（即已经暴露于人类免疫系统的蛋白质），使得当治疗施用时蛋白质不太可能引起人免疫系统。结合蛋白通过重组DNA表达适当地产生。

10. 发明申请

WO1993017105A1 ALTERED ANTIBODIES, PRODUCTS AND PROCESSES RELATING THERETO 审中-公开
标题翻译：改变的抗体，产品和工艺与此有关
公开(公告)号：WO1993017105A1
公开(公告)日：1993-09-02
申请号：PCT/GB1993000363
申请日：1993-02-19
申请人： SCOTGEN LIMITED , WINTER, Gregory, Paul , CARR, Francis, Joseph , HARRIS, William, Joseph
发明人： SCOTGEN LIMITED
IPC分类号： C12N15/13
CPC分类号： C07K16/1027 , A61K38/00 , C07K16/465 , C07K2317/24
摘要： The present invention relates to altered antibodies which are substantially immuno silent by virtue of their containing selected germ-line amino acid residues which replace one or more corresponding somatically mutated residues in a native antibody. In a process for making a gene for use in preparing such an antibody, one or more somatically mutated amino acid residues in a native antibody are identified as suitable candidate(s) for alteration. A nucleotide coding sequence is made which codes for selected germ-line amino acid residues to replace the one or more somatically mutated amino acid residues. The altered antibody can have variable (V) regions which comprise complementarity determining regions (CDRs) which provide the antibody with capacity to bind a specific antigen; and a selected and predominantly germ-line framework. In processes for making a gene for use in the preparation of such an antibody, there are the steps of (i) obtaining CDR encoding nucleotide sequences which encode CDRs with specificity for the specific antigen and (ii) combining these CDR encoding nucleotide sequences with framework encoding nucleotide sequences which encode the selected germ-line framework.
摘要翻译：本发明涉及通过其含有选择的天然抗体中一个或多个相应的体细胞突变残基的选择的种系氨基酸残基基本上免疫沉默的抗体。在制备用于制备这种抗体的基因的方法中，天然抗体中的一个或多个体细胞突变的氨基酸残基被鉴定为用于改变的合适的候选物。编码编码选择的种系氨基酸残基以代替一个或多个体细胞突变的氨基酸残基的核苷酸编码序列。改变的抗体可以具有可变（V）区，其包含提供抗体结合特异性抗原的能力的互补决定区（CDR）; 和所选择的并且主要种系框架。在制备用于制备这种抗体的基因的方法中，存在以下步骤：（i）获得CDR编码核苷酸序列，其编码对特异性抗原具有特异性的CDR，以及（ii）将这些CDR编码核苷酸序列与框架编码所选择的种系框架编码核苷酸序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式